Senior Correspondent, London
Ben's Feed
Jan 14, 2015

AstraZeneca heart drug boosted by major clinical trial success

LONDON (Reuters) – AstraZeneca’s blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the closely watched product.

Giving Brilinta to patients who had a heart attack over a year ago could more than double the number of people eligible for the medicine, which the company has predicted could eventually generate sales of $3.5 billion a year.

Jan 14, 2015
Jan 14, 2015

AstraZeneca heart drug hits goal in major clinical trial

LONDON (Reuters) – AstraZeneca’s blood-thinning drug Brilinta cut the risk of death or heart attack in patients with a history of previous attacks, according to a major clinical trial that will boost hopes for the product.

Using Brilinta in this patient population could more than double the number of people eligible for the medicine, which the company has predicted could eventually generate sales of $3.5 billion a year.

Jan 13, 2015
Jan 12, 2015

J&J strikes Alzheimer’s research deal with Swiss firm AC Immune

LONDON/ZURICH (Reuters) – Johnson & Johnson boosted its research efforts into battling Alzheimer’s on Monday, striking a deal potentially worth more than $500 million to develop anti-tau vaccines with Swiss biotech firm AC Immune.

Tau is a protein known for forming twisted fibers inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.

Jan 12, 2015
Jan 11, 2015
Jan 11, 2015

Shire to buy NPS for $5.2 billion to boost rare disease drugs

LONDON (Reuters) – Shire Plc has agreed to buy NPS Pharmaceuticals Inc for $5.2 billion in its biggest acquisition yet, as the Dublin-based drugmaker strengthens its position in the lucrative field of medicines for rare diseases.

The takeover continues the breakneck pace of deal-making seen in 2014 in the pharmaceuticals sector, where companies are jockeying for promising assets as a wave of new drugs emerges from research laboratories.

Jan 9, 2015
Jan 9, 2015
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben